Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

• Published in: Journal of thoracic oncology Vol. 15; no. 5; pp. 816 - 826
• Main Authors: Gao, Shugeng, Li, Ning, Gao, Shunyu, Xue, Qi, Ying, Jianming, Wang, Shuhang, Tao, Xiuli, Zhao, Jun, Mao, Yousheng, Wang, Bing, Shao, Kang, Lei, Wendong, Wang, Dali, Lv, Fang, Zhao, Liang, Zhang, Fan, Zhao, Ziran, Su, Kai, Tan, Fengwei, Gao, Yibo, Sun, Nan, Wu, Dawei, Yu, Yue, Ling, Yun, Wang, Zhijie, Duan, Chunjian, Tang, Wei, Zhang, Lei, He, Shun, Wu, Ning, Wang, Jie, He, Jie
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2020; Copyright by the International Association for the Study of Lung Cancer
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms - drug therapy; Neoadjuvant; Neoadjuvant Therapy; NSCLC; PD-1 inhibitor; PD-L1 expression; SUVmax; PD-L1 expression; SUVmax; Neoadjuvant; PD-1 inhibitor; NSCLC
• ISSN: 1556-0864; 1556-1380; 1556-1380
• DOI: 10.1016/j.jtho.2020.01.017

Programmed death receptor-1 (PD-1) inhibitors have shown efficacy in first-line treatment of NSCLC; however, evidence of PD-1 inhibitor as neoadjuvant treatment is limited. This is a phase 1b study to evaluate the safety and outcome of PD-1 inhibitor in neoadjuvant setting. Treatment-naive patients with resectable NSCLC (stage IA–IIIB) received two cycles of sintilimab (200 mg, intravenously, day 1 out of 22). Operation was performed between day 29 and 43. Positron emission tomography–computed tomography scans were obtained at baseline and before the operation. The primary end point was safety. Efficacy end points included rate of major pathologic response (MPR) and objective response rate. Expression of programmed cell death ligand 1 was also evaluated (registration number: ChiCTR-OIC-17013726). A total of 40 patients enrolled, all of whom received two doses of sintilimab and 37 underwent radical resection. A total of 21 patients (52.5%) experienced neoadjuvant treatment-related adverse events (TRAEs). Four patients (10.0%) experienced grade 3 or higher neoadjuvant TRAEs, and one patient had grade 5 TRAE. Eight patients achieved radiological partial response, resulting in an objective response rate of 20.0%. Among 37 patients, 15 (40.5%) achieved MPR, including six (16.2%) with a pathologic complete response in primary tumor and three (8.1%) in lymph nodes as well. Squamous cell NSCLC exhibited superior response compared with adenocarcinoma (MPR: 48.4% versus 0%). Decrease of maximum standardized uptake values after sintilimab treatment correlated with pathologic remission (p < 0.00001). Baseline programmed cell death ligand 1 expression of stromal cells instead of tumor cells was correlated with pathologic regression (p = 0.0471). Neoadjuvant sintilimab was tolerable for patients with NSCLC, and 40.5% MPR rate is encouraging. The decrease of maximum standardized uptake values after sintilimab might predict pathologic response.